RAS Mutation Analysis, Thyroid Cancer

Test Code

90479

CPT Codes
81403, 81311, 81275, 81276

Includes

HRAS Mutation
KRAS Mutation
NRAS Mutation

Preferred Specimen

1 formalin-fixed, paraffin-embedded tissue block or needle washing

Minimum Volume

1 tissue block or needle washing

Instructions

Do not reject. Needle washings in alcohol-based fixative (e.g. Cytolyt ^®) or formalin-fixed, paraffin-embedded tissue block FNA or FFPE specimens are acceptable for the assay. All specimens must be accompanied with pathology report. All FFPE specimens will be examined by a pathologist for confirmation and adequacy. Macrodissection, if warranted, is performed in the lab.

Transport Temperature

Room temperature

Specimen Stability

FNA or FFPE
Room temperature: 5 years
Refrigerated: 5 years
Frozen: Unacceptable

Needle washings
Room temperature: 30 days
Refrigerated: 30 days
Frozen: Unacceptable

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

DO NOT REJECT

Methodology
Pyrosequencing

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Sets up 7 days a week.

Clinical Significance

Activating mutations in the RAS genes, particularly NRAS, have been detected in follicular thyroid carcinomas (up to 40%) and papillary thyroid carcinomas (up to 10%), but are also seen commonly in follicular adenomas. Correlation with morphologic and clinical findings is thus required.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.